Correction to: Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways

Xiaolan Lian^{1

2

3}, Yu-Min Lin², Shingo Kozono², Megan K Herbert², Xin Li¹, Xiaohong Yuan¹, Jiangrui Guo¹, Yafei Guo¹, Min Tang¹, Jia Lin¹, Yiping Huang¹, Bixin Wang¹, Chenxi Qiu², Cheng-Yu Tsai², Jane Xie², Ziang Jeff Gao², Yong Wu¹, Hekun Liu³, Xiao Zhen Zhou^{4

5}, Kun Ping Lu^{6

7}, Yuanzhong Chen⁸

Affiliations

¹ Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
² Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
³ Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou, China.
⁴ Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. xzhou@bidmc.harvard.edu.
⁵ Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou, China. xzhou@bidmc.harvard.edu.
⁶ Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. klu@bidmc.harvard.edu.
⁷ Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou, China. klu@bidmc.harvard.edu.
⁸ Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China. chenyz@mail.fjmu.edu.cn.

Published Erratum

Xiaolan Lian et al. J Hematol Oncol. 2018.

. 2018 Jul 11;11(1):94.

doi: 10.1186/s13045-018-0634-0.

¹ Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
² Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
³ Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou, China.
⁴ Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. xzhou@bidmc.harvard.edu.
⁵ Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou, China. xzhou@bidmc.harvard.edu.
⁶ Division of Translational Therapeutics, Department of Medicine and Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. klu@bidmc.harvard.edu.
⁷ Fujian Key Laboratory for Translational Research in Cancer and Neurodegenerative Diseases, Institute for Translational Medicine, Fujian Medical University, Fuzhou, China. klu@bidmc.harvard.edu.
⁸ Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China. chenyz@mail.fjmu.edu.cn.

Abstract

The original article [1] contained minor typesetting errors affecting the following authors: Ziang Jeff Gao, Xiao Zhen Zhou, and Kun Ping Lu.

Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.
Lian X, Lin YM, Kozono S, Herbert MK, Li X, Yuan X, Guo J, Guo Y, Tang M, Lin J, Huang Y, Wang B, Qiu C, Tsai CY, Xie J, Gao ZJ, Wu Y, Liu H, Zhou XZ, Lu KP, Chen Y. Lian X, et al. J Hematol Oncol. 2018 May 30;11(1):73. doi: 10.1186/s13045-018-0611-7. J Hematol Oncol. 2018. PMID: 29848341 Free PMC article.

1. Lian X, et al. Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. J Hematol Oncol. 2018;11:73. doi: 10.1186/s13045-018-0611-7. - DOI - PMC - PubMed